Citations

Clear

1417 citation(s) found for "Simon, FM".

Mayo Clinic Scottsdale Experience With Laparoscopic Nephron Sparing Surgery for Renal Tumors
Simon, Scott D. , Ferrigni, Robert G., Novicki, Donald E., Lamm, Donald L., Swanson, Scott S., Andrews, Paul E. , Swanson, Scott

Mayo Clinic

Journal of Urology | August 25, 2004 | Volume: 169 | Issue: 6 | Pages: 2059-2062

10.1097/01.ju.0000058407.28232.38 | PMID 12771719 Get It

Differential Regulation of TCR-mediated Gene Transcription by Vav Family Members
Zakaria, Shaheen, Gomez, Timothy S., Savoy, Doris N., McAdam, Simon, Turner, Martin , Abraham, Robert T. , Billadeau, Daniel D.

Mayo Clinic

The Journal of Experimental Medicine | February 2, 2004 | Volume: 199 | Issue: 3 | Pages: 429-434

10.1084/jem.20031228 | PMID 14757747 Get It

Although all three Vav family members are expressed in T lymphocytes, the role that Vav3 plays in T cell activation is poorly defined. Here we show that, like Vav1, Vav3 undergoes rapid tyrosine phosphorylation after T cell receptor (TCR) cross-linkage and interacts with the adaptor molecules SLP76 and 3BP2 in a SH2-dependent manner. However, depletion of Vav1 but not Vav3 protein by RNA interference affects TCR-mediated IL-2 promoter activity. In contrast, Vav3 function is specifically required for coupling TCR stimulation to serum response element–mediated gene transcription. These data indicate that, although both Vav proteins are biochemically coupled to the TCR, they regulate distinct molecular pathways leading to defined gene transcriptional events.
Phase II Study of the Efficacy and Safety of Cisplatin-Epinephrine Injectable Gel Administered to Patients With Unresectable Hepatocellular Carcinoma
Leung, Thomas W. T. , Yu, Simon C.H. , Geschwind, J., Engelmann, K., Giovannini, Marc , Stewart, Morgan E., Orenberg, Elaine K., Thuluvath, Paul J. , Johnson, Philip J. , Vogl, Thomas J. , Gores, Gregory J. , O’Grady, John , Heneghan, Michael A.

Mayo Clinic

Journal of Clinical Oncology | February 13, 2003 | Volume: 21 | Issue: 4 | Pages: 652-658

10.1200/jco.2003.04.152 | PMID 12586802 Get It

Purpose: To study the efficacy and safety of percutaneous cisplatin-epinephrine (CDDP-EPI) injectable gel in patients with localized unresectable hepatocellular carcinoma (HCC). Patients and Methods: Eligible patients had histologically proven HCC, no prior treatment except for surgery, and no more than three tumors (each measured ≤ 7 cm, total tumor volume ≤ 200 cm3). They were treated percutaneously under ultrasound or computed tomography (CT) guidance, with up to 10 mL of CDDP-EPI gel (1 mL contains 4 mg of CDDP and 0.1 mg of EPI) per treatment and four treatments in 6 weeks to a maximum of eight treatments. The primary end points were tumor response, defined by change of percentage of tumor necrosis according to CT criteria, and safety. Survival parameters were secondary end points. Results: From June 1997 to April 2000, 58 patients (median age, 65 years) entered the study. All patients were assessable for safety, and 51 were assessable for efficacy. The median number of treatments was four (range, one to eight treatments). Objective response rate was 53% (27 of 51 patients), including 16 complete and 11 partial responses. Of the 27 responders, 14 (52%) subsequently developed progressive disease, but in most of them (93%), a new tumor arose at untreated liver sites. Median survival was 27 months (range, 18.4 to 35.7 months). The 1-, 2-, and 3-year survival rates were 79%, 56%, and 14% respectively. The procedure was well tolerated with only minor side effects. Conclusion: Percutaneous local ablation with CDDP-EPI injectable gel can induce significant tumor necrosis and local control for localized unresectable HCC, and the treatment is well tolerated.
Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics
Baeres, M, Herkel, Johannes , Czaja, Albert J. , Wies, Ingrid, Kanzler, Stephan, Cançado, Eduardo Luiz Rachid , Porta, Gilda , Nishioka, Mikio, Simon, Tracey G. , Daehnrich, Cornelia, Schlumberger, W, Galle, Peter R. , Lohse, Ansgar W. , Galle, Peter Robert

Mayo Clinic

Gut | July 28, 2002 | Volume: 51 | Issue: 2 | Pages: 259-264

10.1136/gut.51.2.259 | PMID 12117891 Get It

Background: Antibodies to soluble liver antigen/liver pancreas (SLA/LP) are specific markers of autoimmune hepatitis. Their target antigen has recently been cloned. Aims: To establish standardised immunoassays using the recombinant antigen, and to assess the frequency and significance of seropositivity in patients from different countries. Methods: An enzyme linked immunoassay was developed using purified recombinant antigen and validated by testing sera from 200 healthy blood donors and 1026 patients with various liver and non-liver diseases. The assay was then applied to 454 sera from 419 patients with autoimmune hepatitis from different countries. All sera were also tested by inhibition immunoassay and western blot. Results: Antibodies were reliably detected by the recombinant immunoassay and occurred exclusively in patients with autoimmune liver disease. Twenty three of 149 patients from the USA (15%), 23/132 from Brazil (17%), 21/108 from Germany (19%), and 2/30 from Japan (7%) were seropositive. Clinical features at presentation were similar between seropositive and seronegative patients. However, relapse after corticosteroid withdrawal or during maintenance therapy occurred more commonly in seropositive patients. Conclusions: Antibodies to SLA/LP can be reliably detected by these standardised immunoassays based on recombinant antigen. Antibodies to SLA/LP occur with similar frequencies in different geographical regions, races, and age groups, and are of exquisite diagnostic specificity. Whether SLA/LP positive patients represent a clinically distinct subgroup remains to be determined; relapse during treatment reduction appeared to be more common in the SLA/LP group.
Looking at Child Labor
Levine, James A. , Weisell, Robert, Chevassus, Simon, Martinez, Claudio D., Burlingame, Barbara

Mayo Clinic

Science | July 27, 2002 | Volume: 296 | Issue: 5570 | Pages: 1025-1026

10.1126/science.296.5570.1025c | PMID 12004902 Get It

The Work Burden of Women
Levine, James A. , Weisell, Robert, Chevassus, Simon, Martinez, Claudio D., Burlingame, Barbara , Coward, W. A.

Mayo Clinic

Science | July 27, 2002 | Volume: 294 | Issue: 5543 | Pages: 812-812

10.1126/science.1064627 | PMID 11679660 Get It

Susceptibility Locus for Alzheimer's Disease on Chromosome 10
Holmans, Peter , Marshall, Helen, Kwon, Jennifer M. , Meyer, David , Ramic, Dzanan, Shears, Shantia, DeVriéze, Fabienne Wavrant, Hamshere, Marian L. , Abraham, Richard, Tunstall, Nigel, Rice, Frances , Carty, Stephanie, Lillystone, Sara, Kehoe, Patrick G. , Rudrasingham, Varuni, Jones, Lesley , Lovestone, Simon , Pérez‐Tur, Jordi , Williams, Julie , Hardy, John , Goate, Alison , Myers, Amanda , Booth, Jeremy , Crook, Richard , Owen, Michael J. , Hardy, John , Goate, Alison M

Mayo Clinic

Science | July 27, 2002 | Volume: 290 | Issue: 5500 | Pages: 2304-2305

10.1126/science.290.5500.2304 | PMID 11125144 Get It

The apolipoprotein E ( APOE ) gene is the only genetic risk factor that has so far been linked to risk for late-onset Alzheimer's disease (LOAD). However, 50 percent of Alzheimer's disease cases do not carry an APOE4 allele, suggesting that other risk factors must exist. We performed a two-stage genome-wide screen in sibling pairs with LOAD to detect other susceptibility loci. Here we report evidence for an Alzheimer's disease locus on chromosome 10. Our stage one multipoint lod score (logarithm of the odds ratio for linkage/no linkage) of 2.48 (266 sibling pairs) increased to 3.83 in stage 2 (429 sibling pairs) close to D10S1225 (79 centimorgans). This locus modifies risk for Alzheimer's disease independent of APOE genotype.